Cargando…

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

The availability of tyrosine kinase inhibitors (TKI) during the past ten years has led to improved response and overall survival of patients suffering from metastatic clear cell renal cell carcinoma (ccRCC). However, most of these tumors will eventually progress due to resistance evolving under ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dietz, Steffen, Sültmann, Holger, Du, YueJun, Reisinger, Eva, Riediger, Anja Lisa, Volckmar, Anna-Lena, Stenzinger, Albrecht, Schlesner, Matthias, Jäger, Dirk, Hohenfellner, Markus, Duensing, Stefan, Grüllich, Carsten, Pahernik, Sascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650322/ https://www.ncbi.nlm.nih.gov/pubmed/29088767 http://dx.doi.org/10.18632/oncotarget.18200

Ejemplares similares

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

Genomic features of renal cell carcinoma with venous tumor thrombus
por: Warsow, Gregor, et al.
Publicado: (2018)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
por: Riediger, Anja Lisa, et al.
Publicado: (2016)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Impact of Surgeon’s Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores
por: Görtz, Magdalena, et al.
Publicado: (2022)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer()
por: Mang, Josef, et al.
Publicado: (2015)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer
por: Eickelschulte, Samaneh, et al.
Publicado: (2022)

Multiple layers of intratumor heterogeneity: clues to clonal evolution of non-small cell lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
por: Bauer, Simone, et al.
Publicado: (2021)

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice
por: Faehling, Martin, et al.
Publicado: (2017)

An artificial intelligence-based chatbot for prostate cancer education: Design and patient evaluation study
por: Görtz, Magdalena, et al.
Publicado: (2023)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?
por: Mechtersheimer, Gunhild, et al.
Publicado: (2021)

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021)

Paraganglioma of the Seminal Vesicle Case Report and Review of the Literature
por: Tosev, Georgi, et al.
Publicado: (2016)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability
por: Tapia-Laliena, María Ángeles, et al.
Publicado: (2019)

Prognostic relevance of androgen receptor expression in renal cell carcinomas
por: Foersch, Sebastian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nm53pdqem28vguu6s3ouq0iu4u